MarkusYMaparaMDPhD

Hematologic Oncology

Professor of Medicine, Director of Blood and Marrow Transplantation, Columbia University Medical Center, New York

Overview of Dr. Mapara

Dr. Markus Mapara is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from University of Heidelberg Faculty of Medicine and has been in practice 27 years. Dr. Mapara accepts several types of health insurance, listed below. He is one of 370 doctors at New York-Presbyterian Hospital and one of 121 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. He also speaks multiple languages, including German and French. He has more than 100 publications and over 500 citings.

Office
161 Ft Washingtn Ave
Herbert Irving Pavilion
New York, NY 10032
Book by Phone+1(231) 787-1035

Fax+1 412-235-1030

Education & Training

University of Heidelberg Faculty of MedicineClass of 1990

Certifications & Licensure

NY State Medical License 2011 - 2027
PA State Medical License 2005 - 2014
Internal MedicineHematology/Oncology

Clinical Trials

Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma Start of enrollment: 2006 Jul 01
Completed
Phase 1
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Start of enrollment: 2006 Nov 01
Completed
Phase 3

Publications & Presentations

PubMed

Improved Outcomes of Myeloma Cast Nephropathy in Newly Diagnosed Multiple Myeloma With Modern Anti-Myeloma Therapies.
Michael Sang Hughes, Metodi Balev, Jai Radhakrishnan, Divaya Bhutani, Markus Mapara
European Journal of Haematology. 2025-02-24
Diffuse Lung Involvement as a Rare Presentation of Systemic AL Amyloidosis: A Retrospective Cohort Study.
Amy Song, George Mellgard, Claudia Bellofiore, Marco Basset, Mario Nuvolone
Blood Advances. 2025-02-20
Cytokines in hematopoietic cell transplantation and related cellular therapies.
Abdul-Hamid Bazarbachi, Markus Y Mapara
Best Practice & Research. Clinical Haematology. 2024-12-01

Journal Articles

Immunomodulatory Drugs Downregulate IKZF1 Leading to Expansion of Hematopoietic Progenitors with Concomitant Block of Megakaryocytic Maturation
Markus Y Mapara, Sara A Monaghan, Suzanne Lentzsch, Haematologica
Brentuximab Vedotin and Bendamustine Produce High Complete Response Rates in Patients with Chemotherapy Refractory Hodgkin Lymphoma
Changchun Deng, Markus Y. Mapara, Ahmed Sawas, Matko Kalac, British Journal of Haematology

Abstracts/Posters

Combination Chemotherapy with Carfilzomib, Bendamustine and Dexamethasone Is Highly Active for Therapy of Newly Diagnosed Multiple Myeloma-Results of Single Center Pha...
Markus Y. Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Excellent Survival and Immune Reconstitution Following Matched/Mismatched Unrelated and Mismatched Related Transplantation in Adult Patients with Sickle Cell Disease: ...
Markus Y Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy
Markus Y. Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study
Markus Y. Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Autologous Transplant Recipients Have a Healthier Gut Microbiota at Baseline and Faster Recovery from Microbiome Injury Compared to Allogeneic Transplant Recipients
Markus Y. Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Checkpoint Inhibitor PD-1H/VISTA Functions As MMP-13 Receptor on Osteoclasts and Mediates MMP-13 Induced Osteoclast Activation in Multiple Myeloma
Markus Y. Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Gck Kinase Activity Is Critical for RAS Mutated Myeloma - a Potential Treatment Approach for Targeting Specific Mutations
Markus Y Mapara, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

How Gene Therapies Are Revolutionizing Care for Sickle Cell DiseaseFebruary 27th, 2025
Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia UniversityJuly 25th, 2024
A Gene Therapy Cure for Sickle Cell Is on the HorizonMarch 15th, 2023
Join now to see all

Grant Support

Binding of MMP13 to Immune Checkpoint Receptor PD-1H links Bone Disease with Immune Suppression in Multiple MyelomaCOLUMBIA UNIVERSITY HEALTH SCIENCES2021–2026
Role Of STAT1 And STAT3 In Graft Versus Host Disease And Graft Versus Leukemia EFNational Heart, Lung, And Blood Institute2008–2011

Professional Memberships

American Society of Hematology - ASH
Member
American Society of Blood and Marrow Transplantation
Member

Other Languages

German, French

External Links

columbia Doctorshttp://columbiadoctors.org/find-a-provider?specialty=&lastname=mapara&insurance=-1&depId=-1&divId=0&language=-1&gender=-1&zipsearch=&pracid=&refine=Search

Insurance Accepted

Empire BCBS PPO
Multiplan PHCS PPO
Multiplan PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment